{
 "name": "南光",
 "slug": "tw-1752",
 "aliases": [
  "南光化學製藥股份有限公司",
  "NANG KUANG",
  "1752"
 ],
 "ticker": "1752",
 "industry": "生技醫療業",
 "website": "http://www.nangkuang.com.tw",
 "summary": "南光（1752）是上市的生技醫療類股公司，1973 年成立，2022 年上市。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "南光化學製藥股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "英文簡稱",
   "value": "NANG KUANG",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "掛牌市場",
   "value": "臺灣證券交易所上市",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "上市日期",
   "value": "2022-01-19",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "成立日期",
   "value": "1973-08-20",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "董事長",
   "value": "陳立賢",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "總經理",
   "value": "陳本松、陳本忠",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "實收資本額",
   "value": 1009884720,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所台南所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "公司網址",
   "value": "http://www.nangkuang.com.tw",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 162083,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔二手來源與混入說明之網址不符本次白名單；已回查官方115年09月營收申報，出表日期1151017，原claim/value/unit/as_of一致，僅修正source並補本註記。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": -14.41,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔二手來源與混入說明之網址不符本次白名單；已回查官方115年09月營收申報，出表日期1151017，原claim/value/unit/as_of一致，僅修正source並補本註記。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": -4.48,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔二手來源與混入說明之網址不符本次白名單；已回查官方115年09月營收申報，出表日期1151017，原claim/value/unit/as_of一致，僅修正source並補本註記。"
  },
  {
   "claim": "管線：ND-340",
   "value": "局部麻醉劑（長效針劑）｜第一期臨床已完成；第二期臨床申請審查中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。 NCT05588557（bupivacaine microsphere）一期登錄已完成：https://clinicaltrials.gov/study/NCT05588557；年報第93頁明確說二期向衛生機關申請審查中，第119頁簡稱進入二期，採較保守且具體的表述。"
  },
  {
   "claim": "管線：ND-558",
   "value": "末梢神經系統藥物｜已送查驗登記｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "管線：ND-571",
   "value": "中樞神經系統藥物（長效針劑）｜處方研究進行中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "催化劑：ND-571",
   "value": "預計完成量產｜2027-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第119頁；原文欄名為「預計完成量產時間」，為公司預估而非主管機關核准時程。"
  },
  {
   "claim": "管線：ND-560",
   "value": "中樞神經系統藥物（長效針劑）｜處方研究進行中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "催化劑：ND-560",
   "value": "預計完成量產｜2027-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第119頁；原文欄名為「預計完成量產時間」，為公司預估而非主管機關核准時程。"
  },
  {
   "claim": "管線：ND-482",
   "value": "肌肉及骨骼系統藥物｜列為計劃開發品項；具體進度未披露｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "管線：ND-566",
   "value": "中樞神經系統藥物｜處方研究進行中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "管線：ND-483",
   "value": "賀爾蒙製劑（長效針劑）｜製程設備研究｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "催化劑：ND-483",
   "value": "預計完成量產｜2027-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第119頁；原文欄名為「預計完成量產時間」，為公司預估而非主管機關核准時程。"
  },
  {
   "claim": "管線：ND-568",
   "value": "抗微生物製劑｜製程設備評估中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "催化劑：ND-568",
   "value": "預計完成量產｜2027-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第119頁；原文欄名為「預計完成量產時間」，為公司預估而非主管機關核准時程。"
  },
  {
   "claim": "管線：ND-544",
   "value": "營養補充劑｜列為計劃開發品項；具體進度未披露｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "管線：ND-545",
   "value": "營養補充劑｜列為計劃開發品項；具體進度未披露｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "管線：ND-569",
   "value": "抗微生物製劑｜製程設備評估中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "催化劑：ND-569",
   "value": "預計完成量產｜2027-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第119頁；原文欄名為「預計完成量產時間」，為公司預估而非主管機關核准時程。"
  },
  {
   "claim": "管線：ND-572~574",
   "value": "代謝性製劑｜處方研究進行中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "催化劑：ND-572~574",
   "value": "預計完成量產｜2027-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第119頁；原文欄名為「預計完成量產時間」，為公司預估而非主管機關核准時程。"
  },
  {
   "claim": "管線：ND-553",
   "value": "抗癌藥物｜列為計劃開發品項；具體進度未披露｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "管線：ND-575",
   "value": "代謝性製劑（長效針劑）｜處方研究進行中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "催化劑：ND-575",
   "value": "預計完成量產｜2027-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第119頁；原文欄名為「預計完成量產時間」，為公司預估而非主管機關核准時程。"
  },
  {
   "claim": "管線：ND-554",
   "value": "血液用藥｜處方研究進行中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "催化劑：ND-554",
   "value": "預計完成量產｜2026-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第119頁；原文欄名為「預計完成量產時間」，為公司預估而非主管機關核准時程。"
  },
  {
   "claim": "管線：ND-581",
   "value": "抗微生物製劑｜製程設備評估中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "催化劑：ND-581",
   "value": "預計完成量產｜2027-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第119頁；原文欄名為「預計完成量產時間」，為公司預估而非主管機關核准時程。"
  },
  {
   "claim": "管線：ND-591",
   "value": "抑制雄性荷爾蒙｜處方研究進行中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "催化劑：ND-591",
   "value": "預計完成量產｜2027-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第119頁；原文欄名為「預計完成量產時間」，為公司預估而非主管機關核准時程。"
  },
  {
   "claim": "管線：ND-594~595",
   "value": "末梢血管擴張劑｜處方研究進行中｜地區未披露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第91–93、119頁。地區、商品名及成分未逐案披露；產品範圍按原文，不推定IND/NDA階段。"
  },
  {
   "claim": "催化劑：ND-594~595",
   "value": "預計完成量產｜2027-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.nangkuang.com.tw/upload/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E5%B0%88%E5%8D%80/%E8%82%A1%E6%9D%B1%E6%9C%83%E7%9B%B8%E9%97%9C%E8%B3%87%E8%A8%8A/%E5%B9%B4%E5%A0%B1/(%E9%99%84%E4%BB%B6%E5%9B%9B)%E8%82%A1%E6%9D%B1%E6%9C%83%E5%B9%B4%E5%A0%B1.pdf",
   "note": "年報PDF第119頁；原文欄名為「預計完成量產時間」，為公司預估而非主管機關核准時程。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-23",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-1752.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}